RSV is the primary contributor to acute lower respiratory infection (primarily pneumonia and bronchiolitis) in young children, with nearly all children experiencing RSV in their first 2 years of life.^1,2
With key experts in the field of RSV, along with the medical journalist Dr Mark Porter, the symposium aims to be an engaging series of interviews, talks, and videos to help raise awareness on this highly prevalent disease and its impact on all infants.

Dr Louis Bont
Paediatric Infectious Diseases Specialist and Leader of the RSV Research Group at the Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands, and of the non-profit ReSViNET foundation

Dr Marta Nunes
Senior researcher at the Vaccine Preventable Diseases Unit/Respiratory and Meningeal Pathogens Research Unit (RMPRU), Soweto, South Africa

Dr Paolo Manzoni
Director of the Department of Paediatrics and Neonatology, ASL Biella, Italy and Coordinator of the Italian Society of Neonatal Infectious Diseases; founding member of the nonprofit ReSViNET foundation

00:00-00:05

Welcome and Introduction
Mark Porter

00:05-00:15

NEWS STORY 1. The perspective of a parent and an HCP on RSV
Louis Bont

00:15-00:25

Live panel discussion
All

00:25-00:40

NEWS STORY 2. RSV – An annual epidemic
Marta Nunes

00:40-00:50

Live panel discussion
All

00:50-01:05

NEWS STORY 3. The true burden of RSV infection in all infants
Paolo Manzoni

01:05-01:15

Live panel discussion
All

01:15-01:25

Live Q&A and panel discussion
All

01:25-01:30

Live summary and close
All

1. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519-30.
2. Bianchini S, et al. Role of Respiratory Syncytial Virus in Pediatric Pneumonia. Microorganisms. 2020;8(12):2048.

This symposium is the first activity supported by Sanofi Pasteur in the context of its new medical education programme around RSV, RATTLE. The main is to help raise awareness around RSV and better equip physicians with key information on the impact of this disease on all infants. RATTLE is being developed in collaboration with key experts in the field, including the symposium faculty.

IMD is a vaccine-preventable disease and yet it remains a considerable threat to people all across the world, particularly infants and adolescents.¹
With personal insights and perspectives from the likes of Prof. Markus Knuf, Prof. Chiara Azzari and Prof. Ener Dinleyici, this symposium offers discussions on this issue. Topics include the difficulty of managing the disease in the intensive care unit, and current and future approaches for prevention.

Prof. Federico Martinón-Torres
Head of Paediatrics and Director of Translational Paediatrics and Infectious Diseases at the Hospital Clínico Universitario de Santiago, Santiago de Composela, Spain.

Prof. Ener Cagri Dinleyici
Professor of Paediatrics at the Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey.

Prof. Chiara Azzari
Professor of Paediatrics, Meyer Children’s University Hospital, Florence, Italy.

Prof. Markus Knuf
Paedeatric Head at the Klinikum Worms in Worms, Germany

• Federico Martinón-Torres – Welcome and introduction including episode one of IMD series.
• Federico Martinón-Torres – Round table discussion and expert perspectives on challenges in IMD diagnosis, critical care and patient management.
• Markus Knuf – Round table discussion and expert perspectives on challenges in IMD diagnosis, critical care and patient management.
• Chiara Azzari- Round table discussion and expert perspectives on challenges in IMD diagnosis, critical care and patient management.
• Ener Cagri Dinleyici – Round table discussion and expert perspectives on challenges in IMD diagnosis, critical care and patient management.
• Chiara Azzari – The current status of IMD and unmet needs.
• Markus Knuf – Advances in IMD vaccination options.
• Federico Martinón-Torres – Discussion and Live Q&A.

1. WHO. Meningococcal meningitis. Available at: https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis. Accessed March 2021.